Imiglucerase: profile and news

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006
Sales of Cerezyme(R) (imiglucerase for injection) are expected to reach $970-$980 million this year, compared with $932 million in 2005. ... - MSN Money

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006
Sales of Cerezyme® (imiglucerase for injection) are expected to reach $970-$980 million this year, compared with $932 million in 2005. ... - WebWire (press release),

Other information

Indication
For treatment of Gaucher's disease (deficiency in glucocerebrosidase)

Pharmacology
Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of alglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside

Mechanism Of Action
Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.

Drug Category
Enzyme replacement

Brand Names/Synonyms
Glucosylceramidase precursor;Beta-glucocerebrosidase;Acid beta-glucosidase;D-glucosyl-N-acylsphingosine glucohydrolase;Alglucerase;Imiglucerase; Ceredase (Genzyme Corp)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human Beta-glucocerbrosidase

Chemical Formula
C2532H3854N672O711S16

Half Life
3.6-10.4 min

Drug Type
Approved Drug

# Accession No
BIOD00037

CAS Registry Number
37228-64-1; 143003-46-7